AxoGen, Inc. (AXGN) Stock

AxoGen, Inc., along with its subsidiaries, specializes in developing and marketing surgical solutions for repairing physical damage or transection to peripheral nerves. The company's flagship products include the Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft designed to bridge severed nerves without the complications of a second surgical site. Additionally, AxoGen offers the AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid that facilitates tensionless repair of severed peripheral nerves, and the AxoGuard Nerve Protector, another porcine submucosa ECM product used to wrap and protect damaged peripheral nerves while preventing soft tissue attachments and reinforcing nerve reconstruction.

Furthermore, AxoGen's product lineup includes the AxoGuard Nerve Cap, a porcine submucosa ECM product that protects the end of a peripheral nerve and isolates it from the surrounding environment to reduce the risk of symptomatic or painful neuroma development. The company also markets the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that serves as a resorbable soft tissue covering to separate tissues in the surgical bed. These innovative solutions highlight AxoGen's commitment to advancing nerve repair and regeneration technologies.

In addition to these core products, AxoGen provides the AxoTouch Two-Point Discriminator, a tool used for measuring the innervation density of the skin's surface area. The company's products are widely used in hospitals, surgery centers, and military hospitals by plastic reconstructive surgeons, orthopedic and plastic hand surgeons, as well as oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European countries, South Korea, and internationally.

Headquartered in Alachua, Florida, AxoGen, Inc. continues to leverage its expertise in nerve repair and regeneration to deliver cutting-edge solutions that improve patient outcomes. The company's focus on innovative surgical products and its expanding global presence underscore its dedication to addressing the critical needs of patients with peripheral nerve injuries.